111 related articles for article (PubMed ID: 15669187)
1. Repeated arsenic trioxide intravenous infusion causes focal bone marrow necrosis in two acute promyelocytic leukemia patients.
Zhou J; Meng R; Sui XH; Yang BF
Chin Med Sci J; 2004 Dec; 19(4):281. PubMed ID: 15669187
[No Abstract] [Full Text] [Related]
2. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
[No Abstract] [Full Text] [Related]
3. Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide.
Ishitsuka K; Shirahashi A; Iwao Y; Shishime M; Takamatsu Y; Takatsuka Y; Utsunomiya A; Suzumiya J; Hara S; Tamura K
Eur J Haematol; 2004 Apr; 72(4):280-4. PubMed ID: 15089767
[TBL] [Abstract][Full Text] [Related]
4. Clinical effects of arsenic trioxide by slowing-intravenous infusion on acute promyelocyte leukemia.
Zhou J; Meng R; Yang BF
Chin Med Sci J; 2005 Jun; 20(2):137. PubMed ID: 16075757
[No Abstract] [Full Text] [Related]
5. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
Au WY; Tam S; Kwong YL
Leuk Res; 2008 Feb; 32(2):357-8. PubMed ID: 17662385
[No Abstract] [Full Text] [Related]
6. Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
Galm O; Fabry U; Osieka R
Leukemia; 2000 Feb; 14(2):343-4. PubMed ID: 10673758
[No Abstract] [Full Text] [Related]
7. Impairment of heart rate variability control during arsenic trioxide treatment for acute promyelocytic leukemia.
Takeshita A; Uehara A; Shinjo K; Naito K; Sahara N; Yamazaki K; Katoh H; Kamikawa T; Ohnishi K; Maekawa M; Hayashi H; Ohno R
Leukemia; 2004 Mar; 18(3):647-8. PubMed ID: 14671633
[No Abstract] [Full Text] [Related]
8. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
9. Hyperleukocytosis from arsenic trioxide.
Levy M; Wofford MM; Powell BL; McLean TW
Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
[TBL] [Abstract][Full Text] [Related]
10. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Barbey JT; Soignet S
Ann Intern Med; 2001 Nov; 135(9):842-3. PubMed ID: 11694116
[No Abstract] [Full Text] [Related]
11. Does arsenic trioxide impact fertility?
Stein EM; Tallman MS
Leuk Lymphoma; 2012 Nov; 53(11):2099-100. PubMed ID: 22524541
[No Abstract] [Full Text] [Related]
12. Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series.
Gupta S; Bagel B; Gujral S; Subramanian PG; Khattry N; Menon H; Nair R
Leuk Lymphoma; 2012 Nov; 53(11):2192-4. PubMed ID: 22452590
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide.
Wilkinson K
Clin J Oncol Nurs; 2001; 5(5):237-8. PubMed ID: 11899773
[No Abstract] [Full Text] [Related]
14. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
15. Use of Novoseven for arsenic trioxide-induced bleeding in PML.
Alimoghaddam K; Ghavamzadeh A; Jahani M
Am J Hematol; 2006 Sep; 81(9):720. PubMed ID: 16804937
[No Abstract] [Full Text] [Related]
16. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
Ducas RA; Seftel MD; Ducas J; Seifer C
J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914
[TBL] [Abstract][Full Text] [Related]
17. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient.
Huang CH; Chen WJ; Wu CC; Chen YC; Lee YT
Pacing Clin Electrophysiol; 1999 Jun; 22(6 Pt 1):965-7. PubMed ID: 10392399
[TBL] [Abstract][Full Text] [Related]
18. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Takeshita A; Sugiyama S; Satoh H; Terada H; Ohno R
Ann Intern Med; 2000 Dec; 133(11):881-5. PubMed ID: 11103058
[TBL] [Abstract][Full Text] [Related]
19. Fluid retention during arsenic trioxide treatment in acute promyelocytic leukemia.
Arai A; Kitano A; Kurosu T; Yamamoto K; Miki T; Murakami N; Miura O
Am J Hematol; 2005 Jul; 79(3):247-8. PubMed ID: 15981228
[No Abstract] [Full Text] [Related]
20. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
Patel SP; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovek S; Kantarjian H; Estey E
Leuk Res; 2006 Mar; 30(3):362-3. PubMed ID: 16168477
[No Abstract] [Full Text] [Related]
[Next] [New Search]
